IN8bio Showcases Consistent Gamma-Delta T Cell Therapy Production at ASGCT 2024

IN8bio, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker INAB, has showcased promising advancements in its gamma-delta T cell therapies at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting in New York. During an oral session, IN8bio detailed its proprietary clinical-scale manufacturing platform for gamma-delta T cells, which has demonstrated robust and reproducible results across various donor populations.

The company presented an oral session titled “Healthy Donor vs. Patient Manufactured Autologous DeltEx DRI Product; Immunophenotyping Gene Expression,” where it released new characterization data. This data highlighted the reproducibility and robust cellular properties of its investigational products. The manufacturing process has shown to enhance markers of potency, effector functions, and trafficking capabilities, which IN8bio believes is a significant step forward in gamma-delta T cell-based therapies.

Dr. Kate Rochlin, Chief Operating Officer of IN8bio, emphasized the importance of these findings. She noted that the new data provide deeper insights into the complex gene-expression changes occurring throughout the manufacturing process. These changes result in a consistent profile for the gamma-delta T cell products by the end of production. Dr. Rochlin explained that the characteristics of the final product are largely driven by the manufacturing process rather than individual donor profiles, which underscores the robustness of IN8bio's manufacturing platform. The aim is to understand how key molecular characteristics can optimize these unique therapies for potentially improved clinical outcomes.

The study involved evaluating T cell receptor repertoire and gene-expression changes from apheresis starting material to the final manufactured gamma-delta T cell products. The samples were taken from both healthy donors and glioblastoma (GBM) patients participating in the INB-200 Phase 1 clinical trial (NCT04165941).

The results showed that the gamma-delta T cell products had significant increases in markers of cellular activation and cytotoxicity. There was also enhanced expression of immune trafficking and stimulation markers, indicating the potential for potent killing, tissue trafficking, and immune cell recruitment in vivo.

Additionally, the data revealed that the gene expression profiles of gamma-delta T cell products from healthy volunteers were highly similar to those from GBM patients. This finding highlights the robustness and reproducibility of the manufacturing process across different donor populations.

IN8bio specializes in developing gamma-delta T cell-based immunotherapies aimed at cancer patients. Gamma-delta T cells are a unique subset of T cells capable of differentiating between healthy and diseased tissue. The company’s leading program, INB-400, is currently in a Phase 2 trial for GBM. Other programs include Phase 1 trials targeting both solid and hematologic tumors, such as INB-200 for GBM and INB-100 for patients undergoing transplantation for hematologic malignancies.

IN8bio’s advancements in gamma-delta T cell therapies represent a significant stride in cancer treatment. The company's consistent and reproducible manufacturing process, combined with the enhanced characteristics of the final gamma-delta T cell products, showcases a strong potential for improving clinical outcomes for cancer patients.